Eyam Vaccines and Immunotherapeutics Welcomes New Board Members and Scientific Advisorswebmaster2022-01-10T21:42:05+00:00January 10th, 2022|
MYND Life Sciences Announces LOI with Eyam Vaccines and Immunotherapeuticswebmaster2021-09-03T18:28:10+00:00June 17th, 2021|
B.C.’s ‘world-class’ biotech sector plays key role in developing COVID-19 treatments and vaccineswebmaster2021-09-03T19:20:03+00:00May 10th, 2021|
Vancouver company in fight to identify COVID-19 variant-killing vaccinewebmaster2021-09-03T19:35:59+00:00April 16th, 2021|
COVID-19: Canadian company testing vaccine candidates that target variant strainswebmaster2021-09-03T19:42:21+00:00April 16th, 2021|
Preclinical Testing of Next-Generation COVID-19 Vaccine Candidates targeting SARS-CoV-2 Variantswebmaster2021-09-03T20:20:25+00:00April 15th, 2021|
Bioinformatics Scientist, Dr. Paolo Ribeca, Joins Eyam Vaccines and Immunotherapeutics’ Scientific Advisory Board webmaster2021-01-27T21:45:28+00:00January 27th, 2021|
Dr. James LaBelle, former Chief Medical Officer of Scripps Health, Joins Eyam Vaccines and Immunotherapeutics Board of Directorswebmaster2021-01-13T21:18:13+00:00January 13th, 2021|
Dr. Lyle Oberg joins the Board of Directors of Eyam Vaccines and Immunotherapeuticswebmaster2020-12-16T23:32:56+00:00December 16th, 2020|
Dave Richardson Joins Eyam Vaccines and Immunotherapeutics Advisory Boardwebmaster2020-12-15T00:06:46+00:00December 10th, 2020|
Eyam Vaccines and Immunotherapeutics Reaches Agreement to License Next-Generation COVID-19 Vaccine Candidates from the University of British Columbiawebmaster2020-12-08T04:45:07+00:00December 2nd, 2020|
Dr. Reno Pontarollo named President and COO of Eyam Vaccines and Immunotherapeuticswebmaster2020-12-01T19:18:58+00:00December 1st, 2020|
The multi-pronged search for the Holy Grail of the pandemic: a vaccinewebmaster2020-07-31T00:11:55+00:00March 18th, 2020|
